ASX:AC8Auscann Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Auscann Group Holdings Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.17 0.00 (0.00 %) (As of 05/12/2020) Add Compare Share Today's RangeA$0.17Now: A$0.17▼A$0.1850-Day Range N/A52-Week RangeA$0.14Now: A$0.17▼A$0.53Volume537,446 shsAverage VolumeN/AMarket Capitalization$53.90 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines AusCann Group Holdings Ltd researches, develops, cultivates, produces, and sells clinically validated cannabis medicines to patients in Australia. The company has a strategic partnership with Tasmanian Alkaloids. AusCann Group Holdings Ltd is headquartered in Joondalup, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Auscann Group. Previous Next 2.1 Community Rank Outperform VotesAuscann Group has received 18 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAuscann Group has received 25 “underperform” votes. (Add your “underperform” vote.)Community SentimentAuscann Group has received 58.14% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Auscann Group and other stocks. Vote “Outperform” if you believe AC8 will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AC8 will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAuscann Group does not currently pay a dividend.Dividend GrowthAuscann Group does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Auscann Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$8,800.00 in company stock and sold A$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Auscann Group is -8.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Auscann Group is -8.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAuscann Group has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.02 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolASX:AC8 Previous Symbol CUSIPN/A CIKN/A Webwww.auscann.com.au Phone61 0 9561 8834Debt Debt-to-Equity Ratio0.30 Current Ratio27.31 Quick Ratio26.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$670,606.00 Price / Sales80.37 Cash FlowA$0.08 per share Price / Cash Flow2.05 Book ValueA$0.12 per share Price / Book1.40Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares317,047,008Market Cap$53.90 million Next Earnings DateN/A OptionableNot Optionable Receive AC8 News and Ratings via Email Sign-up to receive the latest news and ratings for AC8 and its competitors with MarketBeat's FREE daily newsletter. Auscann Group (ASX:AC8) Frequently Asked Questions Has Auscann Group been receiving favorable news coverage? Press coverage about AC8 stock has trended extremely negative on Friday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Auscann Group earned a daily sentiment score of -4.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAuscann Group. Who are some of Auscann Group's key competitors? Some companies that are related to Auscann Group include Benchmark (BMK), Amryt Pharma (AMYT), Green Organic Dutchman (TGOD), WeedMD (WMD), Probiotec (PBP), ESSA Pharma (EPI), CannTrust (TRST), Supreme Cannabis (FIRE), Shield Therapeutics (STX), Althea Group (AGH), Delta 9 Cannabis (NINE), Flowr (FLWR), Depomed (ASRT), Acerus Pharmaceuticals (ASP) and MMJ Group (MMJ). View all competitors. What other stocks do shareholders of Auscann Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Auscann Group investors own include Aurora Cannabis (ACBFF), Auxly Cannabis Group (CBWTF), Corbus Pharmaceuticals (CRBP), EPR Properties (EPR), Freeport-McMoRan (FCX), Fortuna Silver Mines (FSM), Gold Standard Ventures (GSV), Gold Standard Ventures (GSV), InMed Pharmaceuticals (IN) and Insys Therapeutics (INSY). Who are Auscann Group's key executives? Auscann Group's management team includes the following people: Dr. Paul Donald Richard MacLeman MBA, BVSc, Grad Dip Tech, Grad Cert Eng, GAICD, MA, Interim CEO & Exec. Director (Age 53)Mr. Quentin Heath Megson, Chief Operating & Financial Officer and Joint Company Sec. (Age 48)Ms. Susan Patricia Hunter A.C.A., B.Com., BCom, F Fin, ACA, AGIA, FFin, GAIC, Company Sec. (Age 44)Dr. Danial Schecter, Chief Medical Advisor (Age 45) What is Auscann Group's stock symbol? Auscann Group trades on the ASX under the ticker symbol "AC8." What is Auscann Group's stock price today? One share of AC8 stock can currently be purchased for approximately A$0.17. How big of a company is Auscann Group? Auscann Group has a market capitalization of $53.90 million and generates $670,606.00 in revenue each year. What is Auscann Group's official website? The official website for Auscann Group is www.auscann.com.au. How can I contact Auscann Group? The company can be reached via phone at 61 0 9561 8834. This page was last updated on 5/29/2020 by MarketBeat.com Staff
